HNWAG
TPTX

High Net Worth Advisory Group’s Turning Point Therapeutics, Inc. Common Stock TPTX Stock Holding History

High Net Worth Advisory Group’s Portfolio TPTX Stock Details TPTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-500
Closed -$13K – 740
2022
Q1 		$13K Hold
500
– – ﹤0.01% 506
2021
Q4 		$24K Buy
+500
New +$22.4K 0.01% 443

Other funds holding TPTX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

High Net Worth Advisory Group's TPTX Position: Q2 2022 in Review

High Net Worth Advisory Group sold out of Turning Point Therapeutics, Inc. Common Stock (TPTX) in Q2 2022, closing a stake of 500 shares — an estimated $13K sold.

High Net Worth Advisory Group first reported a position in TPTX in Q4 2021 and held it in 2 quarters. The position peaked at $24K in Q4 2021. 208 funds tracked by Wall St. Rank hold TPTX as of Q2 2022.

  • High Net Worth Advisory Group reported no remaining Turning Point Therapeutics, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
  • High Net Worth Advisory Group sold 500 Turning Point Therapeutics, Inc. Common Stock shares in Q2 2022, an estimated $13K.
  • High Net Worth Advisory Group first reported a position in Turning Point Therapeutics, Inc. Common Stock in Q4 2021 and held it in 2 quarters.
  • High Net Worth Advisory Group's Turning Point Therapeutics, Inc. Common Stock position peaked at $24K in Q4 2021.
  • 208 funds tracked by Wall St. Rank held Turning Point Therapeutics, Inc. Common Stock as of Q2 2022.

Based on High Net Worth Advisory Group's 13F filing for Q2 2022, filed 10 Aug 2022.